Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fuji
Julphar
Mallinckrodt
Baxter
Fish and Richardson
Johnson and Johnson
McKesson
Moodys

Generated: September 26, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207026

« Back to Dashboard

NDA 207026 describes PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, which is a drug marketed by Baxter Hlthcare Corp and is included in one NDA. It is available from one supplier. Additional details are available on the PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER profile page.

The generic ingredient in PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is calcium chloride; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate. There are two hundred and seventy-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the calcium chloride; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate profile page.
Suppliers and Packaging for NDA: 207026
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER calcium chloride; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate INJECTABLE;INJECTION 207026 NDA Baxter Healthcare Corporation 24571-116 24571-116-05 2 BAG in 1 CASE (24571-116-05) > 5 L in 1 BAG
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER calcium chloride; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate INJECTABLE;INJECTION 207026 NDA Baxter Healthcare Corporation 24571-116 24571-116-06 2 BAG in 1 CASE (24571-116-06) > 5 L in 1 BAG

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)
Approval Date:Jan 13, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Jan 13, 2022
Regulatory Exclusivity Use:AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthN/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)
Approval Date:Jan 13, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Jan 13, 2022
Regulatory Exclusivity Use:AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Fuji
Citi
Covington
Teva
Chubb
Boehringer Ingelheim
Baxter
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.